Perrigo at 25th Annual Consumer Growth Conference: Strategic Insights Unveiled

At the 25th Annual Consumer Growth and E-Commerce Conference, Perrigo (PRGO) outlined its "Stabilize, Streamline, and Strengthen" strategy, targeting $100-$200 million in incremental revenue from high-growth brands by 2027 and a reduction in net leverage from 4x to below 3x by February 2027. The company anticipates double-digit adjusted EPS growth in 2025, driven by cost management and operational efficiency, while leveraging its store brand presence amid trade-down trends; however, Perrigo acknowledged potential headwinds from tariffs, projecting a $35 million increase in COGS for 2025, and competitive pressures in the infant formula market.

Analysis

Perrigo Company PLC (PRGO) presented its "Stabilize, Streamline, and Strengthen" strategy at the 25th Annual Consumer Growth and E-Commerce Conference, focusing on enhancing its business model within the self-care market. The company is targeting $100-$200 million in incremental revenue from high-growth brands by 2027 and aims to reduce net leverage from approximately 4x to below 3x by February 2027, which includes a $500 million paydown of its payment loan. Management anticipates double-digit adjusted EPS growth in 2025, driven by cost management, operational efficiencies, and leveraging its store brand presence, which saw US OTC volume share increase by 110 basis points in May and 50 basis points in April amid consumer trade-down trends. Despite these positive initiatives, Perrigo acknowledged a projected 1% rise in Cost of Goods Sold (COGS), approximately $35 million in 2025, due to tariffs, and ongoing competitive risks in the infant formula sector. Operationally, US store brand service levels have returned to over 90%, the international brand portfolio has been streamlined to 5-8 key brands, and the infant formula segment has achieved the highest FDA inspection standards alongside launching 60 new SKUs, aiming for a market share exit range of 20-22%. High-growth brands like Compie (a $150 million brand growing over 30%) and Moderna (Perrigo's brand, with net sales up over 35%) are expected to contribute high single-digit growth. The company is also assessing its oral care and derma-cosmetic businesses for potential divestitures as part of its strategic review.

Key Decisions for Investors

• Investors should assess Perrigo's strategic plan for its potential to drive anticipated double-digit adjusted EPS growth in 2025 and achieve targeted net leverage reduction to below 3x by February 2027.
• Key areas to monitor include the realization of $100-$200 million in incremental revenue from high-growth brands by 2027, the management of an expected $35 million COGS increase from tariffs in 2025, and progress in the competitive infant formula market, including achieving the 20-22% market share exit target.
• The ongoing strategic review of oral care and derma-cosmetic businesses presents a potential catalyst; outcomes could impact Perrigo’s business profile and accelerate deleveraging or fund growth investments.